NCT04244656

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: CRISPR Therapeutics AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	CTX120	CTX120 B-cell maturation antigen (BCMA)-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.

Timeline

• Start date: 2020-01-22
• Primary completion: 2024-01-04
• Completion: 2024-01-04
• First posted: 2020-01-28
• Last updated: 2025-01-08

Locations

10 sites across 4 countries: United States, Australia, Canada, Spain

Regulatory

• FDA-regulated drug study